» Articles » PMID: 9563959

Allograft Rejection After Liver Transplantation for Autoimmune Liver Diseases

Overview
Date 1998 Jun 20
PMID 9563959
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune liver diseases (AILD) may progress to liver failure, requiring liver transplantation as definitive therapy, and these immune-mediated disorders may predispose the patient to more frequent graft rejection. The objective of this study was to determine the effect of preexisting AILD on the incidence of allograft rejection after liver transplantation. Sixty-three patients who underwent liver transplantation between March 1988 and December 1994 for AILDs that included autoimmune hepatitis (AIH; n = 33) and primary biliary cirrhosis (PBC; n = 30) were retrospectively compared with 47 patients who underwent liver transplantation for alcoholic cirrhosis during the same time period. There was a lower incidence of acute allograft rejection in patients with AILD who received tacrolimus-based compared with cyclosporine-based immunosuppression (50% v 85.5%; P = .02). However, patients with AILDs overall had a higher incidence of acute rejection than patients with alcoholic cirrhosis (81% v 46.8%; P < .001), regardless of the type of immunosuppression. In addition, steroid-resistant rejection occurred more frequently in patients with AILDs than in patients with alcoholic cirrhosis (38.1% v 12.8%; P = .003). There was also a trend toward a higher incidence of chronic rejection in patients with AILDs compared with patients with alcoholic cirrhosis (11.1% v 2.1%), but this difference did not reach statistical significance. Patient and graft survivals at 1 and 3 years were similar between patients with AILDs and alcoholic liver disease. Compared with alcoholic cirrhosis, preexisting AILDs are associated with a higher incidence of acute allograft rejection and a trend toward more frequent chronic rejection.

Citing Articles

Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with primary biliary cholangitis - an ELTR study.

van Hooff M, de Veer R, Karam V, Adam R, Taimr P, Polak W JHEP Rep. 2024; 6(8):101100.

PMID: 39045337 PMC: 11263784. DOI: 10.1016/j.jhepr.2024.101100.


Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview.

Mercado L, Gil-Lopez F, Chirila R, Harnois D Diagnostics (Basel). 2024; 14(4).

PMID: 38396421 PMC: 10887775. DOI: 10.3390/diagnostics14040382.


Post-Transplant Management and Complications of Autoimmune Hepatitis, Primary Biliary Cholangitis, and Primary Sclerosing Cholangitis including Disease Recurrence.

Henson J, King L Clin Liver Dis. 2023; 28(1):193-207.

PMID: 37945160 PMC: 11033708. DOI: 10.1016/j.cld.2023.07.009.


KASL clinical practice guidelines for management of autoimmune hepatitis 2022.

Clin Mol Hepatol. 2023; 29(3):542-592.

PMID: 37137334 PMC: 10366804. DOI: 10.3350/cmh.2023.0087.


T-cell specific antibody induction versus corticosteroid induction immunosuppression for liver transplant recipients: a meta-analysis.

Jung W, Kuh J, Lim L, Yoo H, Ju J, Lee H Sci Rep. 2023; 13(1):6951.

PMID: 37117258 PMC: 10147598. DOI: 10.1038/s41598-023-32972-z.